Navigation Links
Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System
Date:1/23/2009

QUEBEC, Jan. 23 /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., "Victhom" (TSX: VHB), announced today that its Neurobionix division has achieved ISO 13485:2003 certification for its Quality System Design Control. This certification, an internationally recognized management system standard developed by the International Organization for Standardization (ISO), complements the earlier certification that the Neurobionix division had received back in August 2008 for its manufacturing activities. The combination of both certifications guarantees that the design, development and manufacturing functions of the Company meet the highest quality standards known worldwide for implantable grade medical devices, including neuromodulation systems currently being developed for commercial release late 2009.

"This certification is an additional achievement resulting from the focus the Company has put in the repositioning of the Neurobionix division to become a product development engine capable of bringing innovative products to the market at quality standards expected by the implantable medical device industry and generally associated with larger companies", said Mr. Nader Kameli, Chief Operating Officer of the Neurobionix division.

About Victhom

Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's Neurobionix division focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom's Biotronix division develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics market.

Forward-Looking Statements

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.


'/>"/>
SOURCE VICTHOM HUMAN BIONICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Victhom announces the completion of the second phase of the apnea therapy development
2. Victhom Announces Launch of Enhanced Company Website
3. Victhom to Participate in the OneMedPlace Finance Forum
4. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
5. MultiVu Video Feed: Geron Receives FDA Clearance to Begin Worlds First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
6. Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel
7. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
9. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
10. HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Research Services
11. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 2016 The U.S. Biotechnology industry ... billion of revenue and some $890 billion of total ... global biopharmaceuticals, and this figure is expected to exceed ... up these four equities for assessment: Northwest Biotherapeutics Inc. ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ...
(Date:12/4/2016)... -- In five studies being presented today during the 58th ... in San Diego , researchers are ... of life-saving treatments to patients with a variety of ... therapies directly to the sites in the body where ... advantage over traditional, systemic methods. The studies highlight the ...
(Date:12/2/2016)... , Dec. 2, 2016 More than $4.3 million ... Helix Medals dinner ( DHMD ). The gala was held at ... New York City and honored Alan Alda ... respectively, to health and medicine and the public understanding of ... in 2006, the event has raised $40 million for the ...
(Date:12/2/2016)... -- CytRx Corporation (NASDAQ: CYTR ), a ... announced the appointment of Earl Warren Brien , ... healthcare investor, to its Board of Directors. ... strategic experience at the highest level," said Steven ... of the world,s leading orthopedic surgeons, Dr. Brien has ...
Breaking Biology Technology:
(Date:11/22/2016)... , November 22, 2016 According to the ... IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), ... published by MarketsandMarkets, the market is expected to grow from USD 10.74 ... CAGR of 16.79% between 2016 and 2022. ... ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)... , Nov 15, 2016 Research and Markets ... Forecast to 2021" report to their offering. ... ... 16.18 Billion by 2021 from USD 6.21 Billion in 2016, growing ... Growth of the bioinformatics market is driven by the growing ...
Breaking Biology News(10 mins):